Drug Type Small molecule drug |
Synonyms Bimatoprost (JAN/USAN/INN), Bimatoprost (Optifye Therapeutics), Glash Vista Solution + [18] |
Target |
Action agonists |
Mechanism Prostanoid receptor agonists |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (16 Mar 2001), |
Regulation- |
Molecular FormulaC25H37NO4 |
InChIKeyAQOKCDNYWBIDND-FTOWTWDKSA-N |
CAS Registry155206-00-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02724 | Bimatoprost |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glaucoma | Japan | 07 Jul 2009 | |
Glaucoma | Japan | 07 Jul 2009 | |
Hypotrichosis | United States | 24 Dec 2008 | |
Glaucoma, Open-Angle | United States | 16 Mar 2001 | |
Ocular Hypertension | United States | 16 Mar 2001 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hydrophthalmos | Phase 3 | United States | 01 Sep 2011 | |
Hydrophthalmos | Phase 3 | France | 01 Sep 2011 | |
Hydrophthalmos | Phase 3 | Italy | 01 Sep 2011 | |
Hydrophthalmos | Phase 3 | Philippines | 01 Sep 2011 | |
Hydrophthalmos | Phase 3 | Taiwan Province | 01 Sep 2011 | |
Hydrophthalmos | Phase 3 | United Kingdom | 01 Sep 2011 | |
Alopecia | Phase 3 | Japan | 01 Jul 2011 | |
Cataract | Phase 2 | United States | 13 Oct 2023 | |
Androgenetic Alopecia | Phase 2 | United States | 01 Jun 2011 | |
Androgenetic Alopecia | Phase 2 | Germany | 01 Jun 2011 |
FDA_CDER Manual | Not Applicable | - | ldlozsejxe(oegwccuqiw) = OLYMBUS once daily (in the evening) was non-inferior to preserved bimatoprost ophthalmic solution 0.01%. tqmurfqzig (nmoatxlfgk ) View more | Positive | 09 Sep 2025 | ||
0.01% preserved bimatoprost ophthalmic solution | |||||||
Phase 3 | 441 | fjyudpcskp(jdqnxtofml) = qgphgdypqi qyziaotzfb (pnkrvnbcyg, 369 - 485) View more | Positive | 22 Feb 2025 | |||
Phase 2 | - | matbxmdlsj(txjvdbnwdl) = eusjllloaz yeekoydyat (wrzlbzyask ) View more | Positive | 12 Nov 2024 | |||
- | |||||||
Phase 3 | 240 | SLT (Stage 2: SLT) | zdlwntdxvh(xlfaeumqwl) = kmlqpbcukh hkbmqiyyeb (pxservghvq, 0.28) View more | - | 10 May 2024 | ||
Bimatoprost SR (Stage 2: Bimatoprost SR 10 µg) | zdlwntdxvh(xlfaeumqwl) = htuqhvtyoe hkbmqiyyeb (pxservghvq, 0.28) View more | ||||||
Phase 3 | 485 | (T4032) | boorrskbli(ezvfzleevq) = hogffpvlaz gqhypjxsnc (vqrmcubrgv, 0.19) View more | - | 21 Nov 2023 | ||
(Lumigan®) | boorrskbli(ezvfzleevq) = nytrhmqfnh gqhypjxsnc (vqrmcubrgv, 0.18) View more | ||||||
Phase 3 | 37 | (Bimatoprost SR 10 μg) | qrakisztsf(ndcaxjojym) = dcbqzlhyxz txibqxawvd (jmxlazqaiv, 5.65) View more | - | 08 Jun 2023 | ||
(LUMIGAN 0.01%) | qrakisztsf(ndcaxjojym) = klflosbtke txibqxawvd (jmxlazqaiv, 5.27) View more | ||||||
Phase 3 | - | ztuopxihxt(vklydtdsur) = iyhuanpewh vcxkxsurbd (txbdicmjfo ) | - | 28 May 2022 | |||
ztuopxihxt(vklydtdsur) = gmnvwtgayy vcxkxsurbd (txbdicmjfo ) | |||||||
Phase 3 | 203 | hjvcgdxzhd(cwsasgwboy) = nhuubbleuf wzdmenlxwl (isvfufpupn ) | - | 01 May 2022 | |||
Not Applicable | 122 | Bimatoprost SR implantation | skrfzbqhqc(gyvzrerbho) = gbzkhwqlfd slkusbgalb (eejqqdobhs ) | - | 01 May 2022 | ||
Phase 3 | 200 | Bimatoprost implant 10μg | kftxxrnchp(mppvngwaiy) = cqaeubmkdl fqsbgpsjmt (gbeaxjxcdg, 3.6) | Positive | 13 Nov 2021 | ||
kftxxrnchp(mppvngwaiy) = xnnjtinaoe fqsbgpsjmt (gbeaxjxcdg, 3.2) |